The Egyptian Journal of Radiology and Nuclear Medicine,
Journal Year:
2024,
Volume and Issue:
55(1)
Published: Nov. 29, 2024
Abstract
Background
Breast
cancer
is
one
of
the
most
common
cancers
among
female
population
globally
and
a
major
cause
death
due
to
women.
It
has
been
classified
into
histopathological,
hormonal,
molecular
subtypes
based
on
hormone
receptor
status.
Their
management
involves
multidisciplinary
approach
depending
these
subtypes,
TNM
staging,
tumour
size,
site.
The
purpose
this
study
was
assess
correlation
between
ultrasound
mammography
characteristics
maximum
standardized
uptake
value
PET
with
hormonal
breast
cancer.
Methods
retrospective
from
single-centre
data
available
for
8
months.
In
study,
5
were
considered;
Luminal
A,
B,
HER2-positive
subtype,
HER2-enriched
triple-negative
subtype.
morphology
lesions
analysed
sonography
SUV
max
considered
analyses.
prediction
performance
features
then
analysed.
Results
A
B
had
indistinct
margins
posterior
acoustic
shadowing
ultrasound.
Triple-negative
well-circumscribed
enhancement
characteristically
pleomorphic
microcalcifications
mixed
mammography.
On
PET,
cases
highest
SUV,
subtype
lowest
SUV.
Conclusion
According
our
observations,
there
are
certain
typical
morphological
imaging
each
These
modalities
may
help
radiologists
clinicians
in
stratifying
their
patients
prognostication
better
management.
Frontiers in Immunology,
Journal Year:
2024,
Volume and Issue:
15
Published: Feb. 15, 2024
Impressive
advances
have
been
seen
in
cancer
immunotherapy
during
the
last
years.
Although
breast
(BC)
has
long
considered
as
non-immunogenic,
for
treatment
of
BC
is
now
emerging
a
new
promising
therapeutic
approach
with
considerable
potential.
This
supported
by
plethora
completed
and
ongoing
preclinical
clinical
studies
various
types
immunotherapies.
However,
significant
gap
between
oncology
basic
research
impairs
understanding
immunology
immunotherapy,
hampering
therapy
development.
To
exploit
accumulating
available
data
an
optimal
way,
both
fundamental
mechanisms
at
play
its
pitfalls
must
be
integrated.
Then,
trials
critically
designed
appropriate
combinations
conventional
immunotherapeutic
strategies.
While
there
room
major
improvement,
this
updated
review
details
tools
to
date,
from
bench
bedside,
hope
that
will
lead
rethinking
optimizing
standards
care
patients.
Frontiers in Oncology,
Journal Year:
2024,
Volume and Issue:
14
Published: March 5, 2024
The
fibroblast
activating
protein
(FAP)
is
expressed
by
some
fibroblasts
found
in
healthy
tissues.
However,
FAP
overexpressed
more
than
90%
of
epithelial
tumors,
including
breast
and
gynecological
tumors.
As
a
result,
the
ligand
could
be
used
as
target
for
diagnosis
treatment
purposes.
Positron
emission
tomography/computed
tomography
(PET/CT)
hybrid
imaging
technique
commonly
to
locate
assess
tumor’s
molecular
metabolic
functions.
PET
involves
injection
radiotracer
that
tends
accumulate
metabolically
active
lesions
such
cancer.
Several
radiotracers
have
been
developed
PET/CT
imaging,
fibroblast-activation
inhibitor
(FAPI).
These
tracers
bind
with
high
specificity
affinity,
allowing
non-invasive
detection
quantification
expression
In
this
review,
we
discussed
applications
FAPI
most
common
gynecologic
malignancies.
Radiolabeled
can
improve
detection,
staging,
assessment
response
malignancies,
but
problem
normal
hormone-responsive
organs
remains
insurmountable.
Compared
diagnostic
FAPI,
further
research
needed
future
therapeutic
applications.
International Journal of Oncology,
Journal Year:
2024,
Volume and Issue:
64(5)
Published: April 4, 2024
Compared
with
primary
tumor
sites,
metastatic
sites
appear
more
resistant
to
treatments
and
respond
differently
the
treatment
regimen.
It
may
be
due
heterogeneity
in
microenvironment
between
tumors.
Cancer‑associated
fibroblasts
(CAFs)
are
widely
present
stroma
as
key
components
of
microenvironment.
Primary
CAFs
(pCAFs)
(mCAFs)
heterogeneous
terms
source,
activation
mode,
markers
functional
phenotypes.
They
can
shape
according
organ,
showing
tumors
metastases,
which
affect
sensitivity
these
treatment.
was
hypothesized
that
understanding
pCAFs
mCAFs
provide
a
glimpse
into
difference
outcomes,
providing
new
ideas
for
improving
rate
metastasis
control
various
cancers.
Clinical Nuclear Medicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 9, 2025
Abstract
Breast
cancer
presents
a
significant
global
health
challenge,
necessitating
continued
innovation
in
diagnostic
and
therapeutic
approaches.
Recent
advances
have
led
to
the
identification
of
cancer-associated
fibroblasts,
which
are
highly
prevalent
breast
cancers
express
fibroblast
activation
proteins
(FAPs),
as
critical
targets.
FAP-specific
radiotracers,
when
used
with
PET/CT
SPECT/CT,
potential
for
improving
early
detection,
staging,
treatment
response
monitoring,
intervention.
This
review
provides
insight
into
FAP-targeted
molecular
imaging,
exploring
advanced
techniques
protein
status
assessment,
development
early-phase
targeted
therapies,
other
emerging
applications.
The
advent
imaging
stands
significantly
enhance
personalized
oncologic
care,
leading
improved
management
overall
patient
outcomes.
Clinical Nuclear Medicine,
Journal Year:
2023,
Volume and Issue:
49(1), P. e40 - e41
Published: Nov. 16, 2023
Radiolabeled
fibroblast
activation
protein
inhibitors
(FAPIs)
have
been
extensively
used
in
different
types
of
cancers,
although
not
yet
FDA
approved.
Normal
patterns
FAPI
biodistribution
investigated,
and
it
is
known
that
expressed
nonmalignant
pathophysiological
lesions,
characterized
by
tissue
remodeling
such
as
atherosclerosis,
arthritis,
scar/fibrotic
tissues.
In
this
interesting
image,
we
are
presenting
the
accumulation
68Ga-FAPI
gallbladder.
This
finding
could
be
related
to
a
normal
distribution
radiotracer
physiologic
finding.
potentially
important
may
theragnostic
agent
future.
Diagnostics,
Journal Year:
2023,
Volume and Issue:
13(20), P. 3199 - 3199
Published: Oct. 13, 2023
In
2020,
the
Global
Cancer
Observatory
estimated
incidence
of
colorectal
cancer
(CRC)
at
around
10.7%
coupled
with
a
mortality
rate
9.5%.
The
explanation
for
these
values
lies
in
tumor
microenvironment
consisting
extracellular
matrix
and
cancer-associated
fibroblasts
(CAFs).
Fibroblast
activation
protein
(FAP)
offers
promising
target
therapy
since
its
functions
contribute
to
progression.
Immunohistochemistry
examination
FAP,
fibronectin
ED-B,
CXCR4
primary
tumors
their
respective
synchronous
and/or
metachronous
metastases
along
semiquantitative
analysis
have
been
carried
out
on
histological
samples
50
patients
diagnosed
metastatic
CRC.
intensity
articulated
by
both
"Intensity
%"
score",
is
lower
first
metastasis
compared
statistically
significant
correlation.
No
correlations
observed
regarding
ED-B
CXCR4.
Tumors
that
produce
FAP
an
ambivalent
relationship
this
protein.
At
first,
they
exploit
but
later
reduce
expressiveness.
Although
our
study
has
not
directly
included
FAP-Inhibitor
(FAPI)
PET/CT,
considerable
expression
reveals
potential
as
diagnostic
therapeutic
tool
worthy
further
investigation.
This
dynamic
between
substantial
implications.
